SPDR S&P Biotech ETF
522 hedge funds and large institutions have $9.36B invested in SPDR S&P Biotech ETF in 2020 Q2 according to their latest regulatory filings, with 127 funds opening new positions, 185 increasing their positions, 126 reducing their positions, and 56 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
522
Holders Change
+66
Holders Change %
+14.47%
% of All Funds
10.73%
Holding in Top 10
17
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+21.43%
% of All Funds
0.35%
New
127
Increased
185
Reduced
126
Closed
56
Calls
$1.13B
Puts
$3.12B
Net Calls
-$1.99B
Net Calls Change
-$959M
Top Buyers
| 1 |
DFO
Duquesne Family Office
New York
|
+$123M |
| 2 |
JPMorgan Chase & Co
New York
|
+$80.8M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$34.4M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$28.1M |
| 5 |
WKKFT
W.K. Kellogg Foundation Trust
Battle Creek,
Michigan
|
+$28.1M |
Top Sellers
| 1 |
Citigroup
New York
|
-$284M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$226M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$215M |
| 4 |
Morgan Stanley
New York
|
-$163M |
| 5 |
N
Natixis
Paris,
France
|
-$155M |
